title: Valvular heart disease in antiphospholipid syndrome.
abstract: Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %. The definition is based on the presence of thickening or vegetation of the valves (mainly mitral and aortic) as described by Libman and Sacks for patients with systemic lupus erythematosus (SLE). Transthoracic and/or transoesophageal echocardiography (TTE and TEE, respectively) enable early and accurate diagnosis and help avoid misdiagnosis as rheumatic valve disease. The presence of antiphospholipid antibodies (aPL) in SLE patients is associated with a threefold greater risk of HVD, confirming the crucial importance of these antibodies in the pathogenic process, leading to thrombotic manifestations on valves because of hypercoagulability. Natural history is characterized by worsening of HVD over time with an increased risk for stroke. APS patients undergoing valve-replacement surgery are at high risk of thrombotic and bleeding complications. Thus aPL-associated HVD has affects clinical management of APS patients.
authors: Vascular Medicine Division and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, Centre Hospitalier Universitaire Nancy, Nancy, 54000, France. s.zuily@chu-nancy.fr
authors: Stéphane
authors: S
authors: Zuily
authors: Olivier
authors: O
authors: Huttin
authors: Shirine
authors: S
authors: Mohamed
authors: Pierre-Yves
authors: PY
authors: Marie
authors: Christine
authors: C
authors: Selton-Suty
authors: Denis
authors: D
authors: Wahl
mesh_terms: D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000503:physiopathology; D006349:Heart Valve Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D006801:Humans